查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922955

全磁浮心室輔助裝置市場按幫浦植入部位、年齡層、保險覆蓋範圍、應用和最終用戶分類－2026年至2032年全球預測

Fully MagLev Ventricular Assist Device Market by Pump Placement, Age Group, Insurance Coverage Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年全磁浮心室輔助裝置市值為 6.4567 億美元，預計到 2026 年將成長至 7.3549 億美元，年複合成長率為 15.67%，到 2032 年將達到 17.8913 億美元。

主要市場統計數據
基準年 2025 6.4567億美元
預計年份：2026年 7.3549億美元
預測年份：2032年 17.8913億美元
複合年成長率 (%) 15.67%

本文精彩概述了新一代磁浮心室輔助裝置如何改變臨床實務模式和醫療服務模式。

機械循環支援領域正經歷快速變革時期，這主要得益於技術進步和臨床實踐的不斷發展。全磁浮心室輔助裝置代表了數十年來泵浦機械、材料科學和臨床整合方面不斷改進的結晶。這些裝置旨在最大限度地減少血流動力學壓力，降低血栓風險，延長裝置使用壽命，同時實現微創手術，並提高患者的生活品質。它們的出現不僅是技術的漸進式發展，更是對長期支持的期望的重新定義，並拓展了關於復健過渡、移植過渡和最終治療方案的臨床討論。

磁浮泵動態技術的進步、數位化整合以及不斷發展的臨床通訊協定，如何共同重塑其應用管道和醫療服務模式

隨著技術、臨床證據和醫療系統能力的融合，心室輔助性治療領域正經歷變革性的轉變。磁浮泵可減少摩擦和機械磨損，從而直接提高裝置的耐用性並降低裝置相關溶血的發生率。這項技術進步正在推動臨床通訊協定的變革，外科醫生和心臟團隊正在重新思考植入時機、抗凝血方案和門診管理途徑，以最佳化長期療效。同時，微創植入技術和更短的加護病房住院時間也日益普及，從而重塑了醫院資源的利用方式和病患的復原過程。

2025年美國新貿易措施的綜合影響將波及整個增值分銷（VAD）生態系統的供應鏈韌性、採購經濟性和戰略製造決策。

2025年推出的關稅和貿易政策變化進一步加劇了現有供應鏈的脆弱性，迫使心室輔助裝置生態系統中的各相關人員重新思考其籌資策略。零件和成品進口關稅的提高正在對醫療保健系統的單位成本、採購週期和資本配置決策產生連鎖反應。為此，製造商正在重新評估其全球運營，並加快近岸外包和本地化生產的步伐，以降低跨境貿易波動帶來的風險，並維持可預測的利潤率。

深入洞察應用程式、終端用戶環境、泵浦的位置、患者人口統計特徵和保險計劃如何共同決定產品和市場策略。

特定細分市場的趨勢正在潛移默化地影響全磁浮設備的臨床和商業策略。在考慮應用情境時，裝置設計和管道整合必須涵蓋從過渡治療到復健、追蹤觀察移植和最終治療的整個過程。特別是擇期移植追蹤觀察，由於臨床終點和手術全期需求不同，需要針對長期和短期使用制定差異化的策略。就終端使用者而言，門診中心需要簡化的門診管理功能和追蹤通訊協定，而心臟照護中心則強調急性期和亞急性期照護之間的工作流程整合。從社區醫院到三級醫療中心，各類醫院都需要可擴展的解決方案，以適應不同的患者數量、外科醫生經驗水平和重症監護資源。

監管多樣性、基礎設施差異以及關鍵區域的支付方生態系統如何塑造磁浮輔助裝置（VAD）的不同應用管道

區域趨勢對全磁浮心室輔助裝置的臨床導入管道、監管反應和商業性策略有顯著影響。在美洲，先進的臨床基礎設施和集中式卓越中心支持新技術快速應用，但分散的支付體系和各州不同的採購政策要求制定量身定做的報銷策略並提供強力的衛生經濟學證據。在歐洲、中東和非洲，監管環境各異，集中核准和各國不同的報銷談判給相關人員帶來了挑戰。這為分階段市場進入和區域性客製化的臨床試驗設計提供了機遇，以證明其相對價值。

為了確保永續的競爭優勢，將設備創新、臨床證據產生和服務導向商業化相結合的策略競爭定位和合作管道至關重要。

全磁浮心室輔助裝置領域的競爭格局呈現出多元化的特點：既有不斷拓展產品線的成熟醫療設備製造商，也有憑藉核心泵浦感測器技術進行創新的敏捷型Start-Ups，還有為大規模生產提供支援的專業契約製造。市場領導往往注重患者的整體管理，而不僅僅是設備硬體，並充分利用其深厚的臨床關係、廣泛的術後護理網路和整合服務。新參與企業則通常專注於設計創新，例如減少抗凝血藥物的使用或簡化控制器，並尋求策略性的臨床合作夥伴關係，以檢驗產品在實際應用中的表現。

為製造商和醫療領導者提供實際有效的步驟，以將磁浮設備的創新轉化為持續的臨床應用和商業性成功。

行業領導者應優先考慮一系列綜合舉措，以將技術潛力轉化為持續的臨床和商業性成功。首先，產品開發必須與明確的臨床應用相契合，確保設計功能能夠滿足各種需求，例如復健過渡、移植過渡、短期和長期應用以及最終治療。同時，投資臨床醫生培訓和卓越中心計畫將加速安全應用，最佳化早期治療效果，並建立更廣泛的醫療保險報銷所需的臨床證據基礎。

我們採用透明、多維度的研究途徑，整合臨床訪談、真實世界數據和監管審查，以檢驗研究結果並識別實際限制因素。

本報告的研究結合了結構化的初級和二級研究方法，旨在確保研究結果的可靠性和多方驗證。初級資料收集包括對心臟病學和心胸外科領域的關鍵高管、急診醫院的採購和供應鏈總監以及醫療設備製造商和服務供應商的高級商業領導進行深度訪談。此外，還透過專家圓桌會議和諮詢小組來檢驗新出現的主題，並揭示實際應用中遇到的挑戰。

這是一份簡潔、全面且全面的分析報告，重點闡述了醫療設備創新、證據產生和系統層級策略之間的相互依存關係，而這些關係對於實現廣​​泛的臨床影響至關重要。

全磁浮心室輔助裝置代表了機械循環支援領域的突破，其臨床效益遠超泵性能的提升。隨著技術的日趨成熟，各環節——包括產品開發、臨床證據產生、供應鏈韌性以及與支付方的合作——的協調策略對於這些裝置順利應用於常規臨床實踐至關重要。相關人員應認知到，裝置性能本身並不能保證其被廣泛採用；整合的服務模式、以患者為中心的、可證實的療效以及切實可行的報銷策略同樣重要。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 全磁浮心室輔助裝置市場（依泵浦安裝位置分類）

  • 體外
  • 內式
    • 腹部
    • 胸部
  • 外部援助

9. 依年齡層別分類的全磁浮心室輔助裝置市場

  • 成人
  • 兒童

第10章 保險覆蓋範圍下的全磁浮心室輔助裝置市場

  • 私人的
  • 民眾

第11章 全磁浮心室輔助裝置市場（依應用分類）

  • 通往復健的橋樑
  • 移植橋樑
    • 長期
    • 短期
  • 最終治療

第12章 全磁浮心室輔助裝置市場（依最終用戶分類）

  • 門診治療中心
  • 心臟護理中心
  • 醫院
    • 區域醫療設施
    • 三級醫療機構

第13章 各地區全磁浮心室輔助裝置市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 全磁浮心室輔助裝置市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國全磁浮心室輔助裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國全磁浮心室輔助裝置市場

第17章 中國全磁浮心室輔助裝置市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • CH Biomedical Co., Ltd.
  • CorWave SA
  • Evaheart Inc.
  • Jarvik Heart Inc.
  • Leviticus Cardio LLC
  • Medtronic plc
  • ReliantHeart Inc.
  • Shenzhen Core Medical Technology Co., Ltd.
  • Suzhou Tongxin Medical Devices Co., Ltd.
  • SynCardia Systems LLC
  • Teleflex Incorporated
Product Code: MRR-867BED9A9E80

The Fully MagLev Ventricular Assist Device Market was valued at USD 645.67 million in 2025 and is projected to grow to USD 735.49 million in 2026, with a CAGR of 15.67%, reaching USD 1,789.13 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 645.67 million
Estimated Year [2026] USD 735.49 million
Forecast Year [2032] USD 1,789.13 million
CAGR (%) 15.67%

An engaging overview of how next-generation magnetic levitation ventricular assist devices are altering clinical practice paradigms and healthcare delivery models

The field of mechanical circulatory support has entered a phase of rapid transition, driven by technological advances and evolving clinical practice. Fully magnetically levitated ventricular assist devices represent a culmination of decades-long refinement in pump mechanics, materials science, and clinical integration. These devices are engineered to minimize blood trauma, reduce thrombosis risk, and extend device longevity while enabling less invasive surgical approaches and improved patient quality of life. Their emergence is not merely incremental; it redefines expectations for long-term support and expands the clinical conversation around options for bridge to recovery, bridge to transplant, and destination therapy.

Clinicians and healthcare systems are assessing these systems not only for their hemodynamic performance but also for their implications across care pathways. Advances in materials and pump dynamics have influenced perioperative management, anticoagulation strategies, and outpatient follow-up models. Concurrently, digital monitoring and remote patient management capabilities are increasingly integrated into device ecosystems, enabling proactive complication detection and more reliable longitudinal care. As a result, stakeholders from clinicians and hospital administrators to payers and device manufacturers are re-evaluating protocols for patient selection, training, and infrastructure investment. This introduction frames the broader landscape and sets the stage for a detailed examination of market shifts, segmentation dynamics, regional differences, and strategic priorities that follow.

How technical refinements in maglev pump mechanics, digital integration, and evolving clinical protocols are jointly reshaping adoption pathways and care delivery

The landscape for ventricular assist therapy is undergoing transformative shifts as technology, clinical evidence, and health system capabilities converge. Magnetically levitated pumps have reduced friction and mechanical wear, which directly influences device durability and lowers the incidence of device-related hemolysis. This technical progress is catalyzing changes in clinical protocols, with surgeons and heart teams reconsidering implantation timing, anticoagulation regimens, and outpatient management pathways to optimize long-term outcomes. At the same time, minimally invasive implantation techniques and shorter intensive care unit stays are progressively feasible, reshaping hospital resource utilization and patient recovery trajectories.

Concurrently, digital health integration has accelerated, with telemonitoring and remote diagnostics providing richer streams of patient data that inform adherence, early complication detection, and tailored therapy adjustments. These capabilities support models of decentralized care that can extend specialist oversight into ambulatory centers and community hospitals. Regulatory environments are also adapting, with agencies emphasizing robust post-market surveillance and real-world evidence to validate long-term safety and performance. Moreover, procurement decision-making is increasingly influenced by total cost of care considerations and payer engagement, prompting manufacturers to design solutions that align clinical value with economic sustainability. Together, these shifts underscore a transition from isolated device adoption toward system-level integration, where device performance, care delivery models, and reimbursement strategies must co-evolve to create sustained clinical and commercial success.

The aggregate influence of new US trade measures in 2025 on supply chain resilience, procurement economics, and strategic manufacturing decisions across the VAD ecosystem

The introduction of tariffs and trade policy changes in 2025 has compounded preexisting supply chain fragilities and compelled stakeholders to rethink sourcing strategies across the ventricular assist device ecosystem. Increased import duties on components and finished devices have cascading effects on unit pricing, procurement cycles, and capital allocation decisions within health systems. In response, manufacturers are revisiting their global operations, accelerating nearshoring and regional manufacturing initiatives to mitigate exposure to cross-border trade volatility and to preserve predictable margins.

Moreover, tariffs influence the economics of aftermarket services and spare parts distribution, prompting healthcare providers to reconsider inventory strategies and to seek contractual assurances on service-level agreements. As a result, stakeholders are placing higher value on transparent cost structures and predictable logistics. Policy shifts also affect investment flows, where heightened import costs can delay new product introductions into certain markets and incentivize domestic partnering or licensing arrangements. Consequently, device developers and suppliers are placing greater emphasis on resilient procurement models, flexible manufacturing footprints, and strategic partnerships to maintain supply continuity and to support consistent clinical access despite an increasingly complex international trade environment.

Actionable insights into how application, end user environments, pump placement, patient age groups, and insurance frameworks jointly dictate product and market strategies

Segment-specific dynamics are shaping both clinical and commercial strategies for fully magnetically levitated devices in nuanced ways. When considering application, device design and pathway integration must accommodate the full continuum from bridge to recovery to bridge to transplant and destination therapy, with the bridge to transplant indication requiring differentiated strategies for long-term and short-term use given divergent clinical endpoints and perioperative demands. In terms of end users, ambulatory centres demand streamlined outpatient management features and simplified follow-up protocols, while cardiac care centres emphasize integrated acute and subacute workflows; hospitals, whether community or tertiary, require scalable solutions that address varied volumes, surgeon experience, and intensive care resources.

Pump placement introduces further complexity: extracorporeal options prioritize rapid deployment and temporary support, paracorporeal solutions balance mobility with durability for select cases, and intracorporeal devices-whether abdominal or thoracic-present distinct surgical approaches, imaging considerations, and patient comfort profiles. Age group segmentation drives both design decisions and clinical pathways, as adult patients and pediatric cohorts differ substantially in anatomical constraints, growth considerations, and long-term management needs. Finally, insurance coverage type shapes access and adoption; private coverage often correlates with faster device uptake and broader reimbursement for novel applications, whereas public coverage frameworks emphasize cost-effectiveness and outcome evidence, requiring manufacturers to demonstrate measurable clinical benefits and reliable longitudinal performance. Together, these segmentation layers require integrated product development and market access strategies that align device capabilities with the clinical realities and payer expectations of each segment.

How regional regulatory diversity, infrastructure variance, and payer ecosystems across key geographies shape differentiated adoption pathways for maglev VADs

Regional dynamics are strongly influential in determining clinical adoption pathways, regulatory navigation, and commercial approaches for fully magnetically levitated ventricular assist systems. In the Americas, advanced clinical infrastructure and concentrated centers of excellence support rapid uptake of novel technologies, yet fragmented payer systems and varying state-level procurement policies require tailored reimbursement strategies and robust health economic evidence. Transitioning to Europe, Middle East & Africa, stakeholders face a heterogeneous regulatory landscape, where centralized approvals coexist with country-specific reimbursement negotiations, creating opportunities for staged market entry and region-specific clinical trial design to demonstrate comparative value.

In the Asia-Pacific region, rising cardiovascular disease burden, expanding tertiary care networks, and increasing local manufacturing capacity combine to create a dynamic environment for uptake. However, adoption trajectories differ between high-income urban centers and more resource-constrained settings, prompting manufacturers to consider modular product offerings and scalable service models. Across all regions, clinician training, post-market surveillance, and supply chain localization remain critical enablers of adoption. Moreover, regional reimbursement pathways and procurement norms drive the prioritization of evidence generation and value communication, necessitating differentiated market entry plans that respect local health system structures and patient access imperatives.

Strategic competitive positioning and collaborative pathways that combine device innovation, clinical evidence generation, and service-oriented commercialization for sustained advantage

Competitive dynamics in the fully magnetically levitated ventricular assist device arena are characterized by a mix of established medical device companies extending portfolios, agile startups innovating on core pump and sensor technologies, and specialized contract manufacturers supporting scale-up. Market leaders tend to leverage deep clinical relationships, broad aftercare networks, and integrated service offerings to differentiate on total patient management rather than on device hardware alone. New entrants frequently focus on disruptive aspects of design-such as reduced anticoagulation requirements or simplified controllers-and seek strategic clinical partnerships to validate real-world performance.

Intellectual property and clinical evidence are central competitive levers, with firms investing in multicenter registries, investigator-initiated studies, and outcomes research to demonstrate superior safety and quality-of-life impacts. In parallel, alliances with surgical societies, training consortia, and digital health vendors are becoming more common as companies aim to deliver end-to-end solutions that include remote monitoring and predictive maintenance. Supply chain partnerships and regional manufacturing agreements also play a critical role in competitive positioning, enabling faster time-to-market and localized service support. Ultimately, successful companies will harmonize technical innovation with robust clinical data generation, scalable manufacturing, and a service-oriented commercial approach to meet the complex needs of patients and providers.

Practical, high-impact steps for manufacturers and healthcare leaders to translate MagLev device innovation into sustained clinical adoption and commercial success

Industry leaders should prioritize a set of integrated actions to convert technological promise into durable clinical and commercial success. First, aligning product development with distinct clinical applications-ensuring that design features meet the divergent needs of bridge to recovery, bridge to transplant short-term and long-term use cases, and destination therapy-will be essential. Parallel investments in clinician training and center-of-excellence programs will accelerate safe adoption and optimize early outcomes, thereby building the clinical evidence base required for broader reimbursement.

Second, strengthening supply chain resilience through regional manufacturing, dual sourcing of critical components, and strategic inventory planning can mitigate trade-related disruptions and reduce time-to-service for critical parts. Third, engaging payers proactively to articulate value propositions that reflect total cost of care and patient-centered outcomes will facilitate constructive reimbursement discussions and support access. Fourth, integrating digital monitoring and predictive analytics into device ecosystems will enhance remote care capabilities and help differentiate offerings on service performance. Finally, forging partnerships with surgical societies, patient advocacy groups, and post-market data consortia will accelerate evidence generation and trust in novel therapies. Taken together, these measures create an interdependent strategy that balances innovation, operational resilience, and payer-aligned value demonstration.

A transparent, multi-source research approach integrating clinical interviews, real-world evidence, and regulatory review to validate insights and identify practical constraints

The research underpinning this report combines structured primary and secondary methodologies designed to ensure robust, triangulated insights. Primary data collection included in-depth interviews with clinical key opinion leaders across cardiology and cardiothoracic surgery, procurement and supply chain executives from acute care institutions, and senior commercial leaders from device manufacturers and service providers. These qualitative engagements were complemented by expert roundtables and advisory panels to validate emergent themes and to surface practical implementation challenges experienced in real-world settings.

Secondary research encompassed a thorough review of peer-reviewed clinical literature, device registries, regulatory filings, and technology white papers to contextualize device performance, safety profiles, and procedural trends. Real-world evidence from post-market surveillance reports and health system case studies informed understanding of utilization patterns and care pathway adaptations. Data synthesis relied on methodological triangulation, cross-referencing multiple evidence sources to validate findings and to identify gaps. Recognizing inherent limitations, including variability in reporting standards and evolving regulatory requirements, the approach emphasizes transparency and confidence grading for key insights to support informed decision-making by stakeholders.

A succinct synthesis highlighting the interdependence of device innovation, evidence generation, and system-level strategies necessary to realize widespread clinical impact

Fully magnetically levitated ventricular assist devices represent a pivotal advancement in mechanical circulatory support, offering meaningful clinical benefits that extend beyond incremental pump performance. As technical maturation continues, the successful translation of these devices into routine care depends on coordinated strategies across product development, clinical evidence generation, supply chain resilience, and payer engagement. Stakeholders must recognize that device performance alone will not guarantee adoption; rather, integrated service models, demonstrable patient-centered outcomes, and pragmatic reimbursement strategies are equally critical.

Looking ahead, collaboration between manufacturers, clinicians, health systems, and payers will be central to realizing the full potential of maglev VADs. By committing to transparent post-market surveillance, targeted clinician training, and region-specific market access strategies, stakeholders can facilitate safe, equitable expansion of these therapies. The evolving policy environment and ongoing innovation in digital health present opportunities to redesign care pathways that improve patient experience while maintaining system sustainability. In sum, the path forward requires sustained evidence generation, adaptive operational planning, and a shared focus on delivering measurable clinical and economic value to patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fully MagLev Ventricular Assist Device Market, by Pump Placement

  • 8.1. Extracorporeal
  • 8.2. Intracorporeal
    • 8.2.1. Abdominal
    • 8.2.2. Thoracic
  • 8.3. Paracorporeal

9. Fully MagLev Ventricular Assist Device Market, by Age Group

  • 9.1. Adult
  • 9.2. Pediatric

10. Fully MagLev Ventricular Assist Device Market, by Insurance Coverage Type

  • 10.1. Private
  • 10.2. Public

11. Fully MagLev Ventricular Assist Device Market, by Application

  • 11.1. Bridge To Recovery
  • 11.2. Bridge To Transplant
    • 11.2.1. Long Term
    • 11.2.2. Short Term
  • 11.3. Destination Therapy

12. Fully MagLev Ventricular Assist Device Market, by End User

  • 12.1. Ambulatory Centres
  • 12.2. Cardiac Care Centers
  • 12.3. Hospitals
    • 12.3.1. Community
    • 12.3.2. Tertiary

13. Fully MagLev Ventricular Assist Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Fully MagLev Ventricular Assist Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fully MagLev Ventricular Assist Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Fully MagLev Ventricular Assist Device Market

17. China Fully MagLev Ventricular Assist Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Berlin Heart GmbH
  • 18.7. BiVACOR Inc.
  • 18.8. CH Biomedical Co., Ltd.
  • 18.9. CorWave SA
  • 18.10. Evaheart Inc.
  • 18.11. Jarvik Heart Inc.
  • 18.12. Leviticus Cardio LLC
  • 18.13. Medtronic plc
  • 18.14. ReliantHeart Inc.
  • 18.15. Shenzhen Core Medical Technology Co., Ltd.
  • 18.16. Suzhou Tongxin Medical Devices Co., Ltd.
  • 18.17. SynCardia Systems LLC
  • 18.18. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTRACORPOREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTRACORPOREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTRACORPOREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ABDOMINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ABDOMINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ABDOMINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THORACIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THORACIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY THORACIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PARACORPOREAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PARACORPOREAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PARACORPOREAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LONG TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LONG TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY LONG TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SHORT TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SHORT TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SHORT TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY CENTRES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AMBULATORY CENTRES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COMMUNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COMMUNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COMMUNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY TERTIARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY TERTIARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY TERTIARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 152. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 179. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 184. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 188. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 190. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 193. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PUMP PLACEMENT, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INTRACORPOREAL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY INSURANCE COVERAGE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA FULLY MAGLEV VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)